Drugs / MLM-CAR44.1 T-cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT04097301 | Aug 2019 → Jun 2021 | acute myeloid leukemia, plasma cell myeloma | AGC Biologics S.p.A. | Terminated | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MLM-CAR44.1 T-cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04097301 ↗ |
| Action | Deplete | “show improved in vitro functions in terms of killing capability, and in vivo antitumor activity against hematological and solid tumors.” PMID 33554732 ↗ May 2021 |
| Modality | Cell therapy | “These autologous T-cells are expanded in vitro in large numbers and genetically modified to express the CAR CD44v6ΔNL gene and thus acquire antitumor functions.” NCT04097301 ↗ |
| Route | Intravenous | “Single intravenous infusion” NCT04097301 ↗ |
| Target | CD44 | “genetically modified to express the CAR CD44v6ΔNL gene and thus acquire antitumor functions.” NCT04097301 ↗ |